This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yeager, N. Articles by Di Cristofano, A. Search for Related Content PubMed PubMed Citation Articles by Yeager, N. Articles by Di Cristofano, A.

Mammalian Target of Rapamycin Is the Key Effector of Phosphatidylinositol-3-OH–Initiated Proliferative Signals in the Thyroid Follicular Epithelium

¹ Human Genetics Program and ² Ovarian Cancer and Tumor Cell Biology Programs, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Requests for reprints: Antonio Di Cristofano, Human Genetics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Phone: 215-214-1647; Fax: 215-214-1623; E-mail: antonio.dicristofano{at}fccc.edu.

Activation of the phosphatidylinositol-3-OH kinase (PI3K) signaling cascade is becoming increasingly recognized as a common feature of thyroid follicular neoplasms. We have recently shown that conditional loss of Pten in the mouse thyroid follicular cells is sufficient to stimulate continuous autonomous growth, leading to a homogeneously hyperplastic gland and to the development of follicular adenomas. Because the PI3K/AKT cascade can activate a plethora of different signaling pathways, it is still unclear which of these may represent the key mitogenic output of PI3K-initiated signaling. Here, we show that the in vivo proliferative response to chronic PI3K activation profoundly relies on the activation of the mammalian target of rapamycin (mTOR)/S6K1 axis, and that mTOR inhibition in Pten mutant mice and cells restores virtually normal proliferation rates, despite the presence of still elevated Akt activity, at least in part by down-regulating cyclins D1 and D3, and without affecting cell survival. [Cancer Res 2008;68(2):444–9]

This article has been cited by other articles:

				L. A. Vuchak, O. M. Tsygankova, G. V. Prendergast, and J. L. Meinkoth Protein Kinase A and B-Raf Mediate Extracellular Signal-Regulated Kinase Activation by Thyrotropin Mol. Pharmacol., November 1, 2009; 76(5): 1123 - 1129. [Abstract] [Full Text] [PDF]

				N. Jin, T. Jiang, D. M. Rosen, B. D. Nelkin, and D. W. Ball Dual Inhibition of Mitogen-Activated Protein Kinase Kinase and Mammalian Target of Rapamycin in Differentiated and Anaplastic Thyroid Cancer J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 4107 - 4112. [Abstract] [Full Text] [PDF]

				K. A. Miller, N. Yeager, K. Baker, X.-H. Liao, S. Refetoff, and A. Di Cristofano Oncogenic Kras Requires Simultaneous PI3K Signaling to Induce ERK Activation and Transform Thyroid Epithelial Cells In vivo Cancer Res., April 15, 2009; 69(8): 3689 - 3694. [Abstract] [Full Text] [PDF]